Role of Contrast-Enhanced Spectral Mammography in the detection of breast cancer
https://doi.org/10.24835/1607-0763-1281
Abstract
Objective: to assess the benefits of using contrast-enhancer spectral mammography in patients with an established category of BI-RADS 4a, 4b according to the results of a standard examination (digital mammography and ultrasound).
Materials and methods. The date of 425 patients with a suspicious category of BI-RADS in the period from 2018 to 2021 were analyzed. As part of the additional examination, all patients underwent contrast-enhanced spectral mammography follow by histological verification of the identified changes. The sensitivity and specificity of the methods were evaluated.
Results. The final diagnosis of breast cancer was established in 247 (58.1%) patients out of 425 women. Multicenter and multifocal growth was diagnosed in 17 (6.8%) patients out of 247, and primary multiple synchronous cancer was detected in 6 (2.4%) patients out of 247. False-positive cases when assessing CESM mainly consisted of: typical and atypical ductal hyperplasia, fibroadenoma, intraductal papilloma.
Conclusion. Contrast-enhancer spectral mammography is a highly sensitive and highly specific method in the detection of malignant tumors of the breast. The method also allows minimizing the number of unwanted interventions in suspicious BI-RADS categories.
About the Authors
A. K. Andronov
Branch “Mammology center (Women’s Health Clinic)”, Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Competing Interests:
Russian Federation
Artem K. Andronov – Head of the department of diagnosis and treatment of breast and reproductive system diseases number 3
86, Sh. Entuziastov, Moscow 111123
Competing Interests:
The authors declare no conflict of interest
A. B. Abduraimov
Branch “Mammology center (Women’s Health Clinic)”, Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Competing Interests:
Russian Federation
Adhamzhon B. Abduraimov – Doct. of Sci. (Med.), Professor, Deputy Director for Educational Activities, Head
86, Sh. Entuziastov, Moscow 111123
Competing Interests:
The authors declare no conflict of interest
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. https://doi.org/10.3322/caac.21660
2. The state of oncological care to the population of Russia in 2021. Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. MNIOI named after Herzen-branch FSBI “NMRRC of Radiology” of the Ministry of Health of Russia. 2022. P. 114 https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskojpomoshhi-naseleniyu-rossii-v-2021-godu.pdf (In Russian)
3. Fletcher S.W., Black W., Harris R. et al. Report of the International Workshop on Screening for Breast Cancer. J. Natl. Cancer. Inst. 1993; 85 (20): 1644–1656. https://doi.org/10.1093/jnci/85.20.1644
4. Mandelson M.T., Oestreicher N., Porter P.L. et al. Breast density as a predictor of mammographic detection of interval-and screen-detected cancers. J. Natl. Cancer Inst. 2000; 92: 1081–1087. https://doi.org/10.1093/jnci/92.13.1081
5. Bozzini A., Nicosia L., Pruneri G. et al. Clinical performance of contrast-enhanced spectral mammography in presurgical evaluation of breast malignant lesions in dense breasts: a single center study. Breast Cancer Res. Treat. 2020; 184 (3): 723–731. https://doi.org/10.1007/s10549-020-05881-2
6. FDA 510(k) clearance for GE Contrast Enhanced Spectral Mammography (CESM). Available online: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103485.pdf
7. Suter M.B., Pesapane F., Agazzi G.M. et al. Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysis. Breast. 2020; 53: 8–17. https://doi.org/10.1016/j.breast.2020.06.005
8. Kuhl C.K. The changing world of breast cancer. Invest. Radiol. 2015; 50: 615–628. https://doi.org/10.1097/rli.0000000000000166
9. Gilbert F.J., Pinker-Domenig K. Diagnosis and Staging of Breast Cancer: When and How to Use Mammography, Tomosynthesis, Ultrasound, Contrast-Enhanced Mammography, and Magnetic Resonance Imaging. Springer, 2019: 155–166. https://doi.org/10.1007/978-3-030-11149-6
10. Oscanchuk E.A Contrast Enhanced Spectral Mammography in the diagnosis of non-palpable breast formations with high tissue density: Autoref. Dis. ... Cand. of Sci. (Med.). Moscow, 2017. 144 p. (In Russian)
11. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System, Reston VA, American College of Radiology; 2013 by D'Orsi C.J., Sickles E.A., Mendelson E.B., Morris E.A. et al. https://www.acr.org/Clinical-Resources/Reportingand-Data-Systems/Bi-Rads
12. Ghaderi K.F., Phillips J., Perry H. et al. Contrast-enhanced Mammography: Current Applications and Future Directions. RadioGraphics. 2019; 39: 1907–1920. https://doi.org/10.1148/rg.2019190079
13. Nori J., Kaur M. Contrast-Enhanced Digital Mammography (CEDM). Springer, 2019: 18–19. https://doi.org/10.1007/978-3-319-94553-8
14. Perry H., Philips J., Dialani V. et al. Contrast-Enhanced mammography: A systematic guide tointerpritation and reporting. Am. J. Roentgenol. 2019; 212: 222–231. https://doi.org/10.2214/AJR.17.19265
15. Wang M., He X., Chang Y. et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis. Breast. 2017; 31: 157–166. https://doi.org/10.1016/j.breast.2016.11.009
16. Brem R.F. Management of breast atypical ductal hyperplasia. Radiology. 2020; 294. https://doi.org/10.1148/radiol.2019192192
17. Yang W.T., Parikh J.R., Stavros A.T. et al. Exploring the negative likelihood ratio and how it can be used to minimize false-positives in breast imaging. Am. J. Roentgenol. 2018; 210: 301–306. https://doi.org/10.2214/AJR.17.18774
18. Houben I.P.L., Van de Voorde P., Jeukens C.R.L.P.N. et al. Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risk and might hold clinical benefits. Eur. J. Radiol. 2017; 94: 31–37. https://doi.org/10.1016/j.ejrad.2017.07.004
Supplementary files
Review
рецензировано
For citations:
Andronov A.K., Abduraimov A.B. Role of Contrast-Enhanced Spectral Mammography in the detection of breast cancer. Medical Visualization. 2023;27(4):81-91. (In Russ.) https://doi.org/10.24835/1607-0763-1281
Views:
713
Email this article 